Cambrian Bio reports positive early human trial results for prediabetes drug (opens in new tab)

Cambrian Bio presented Phase 1b human translational data for ATX-304 at the American Diabetes Association’s 86th Scientific Sessions, held 5–8 June 2026, in New Orleans. The company claims ATX-304 is the first AMPK Network Activator in clinical development and that its mechanism increases cellular glucose uptake and mitochondrial respiration to raise whole-body metabolic rate. The […] The post appeared first on <a href="